POS1305 TREATMENT RESPONSE TO TUMOR NECROSIS FACTOR INHIBITORS IN ADULTS WITH JUVENILE IDIOPATHIC ARTHRITIS: DATA FROM THE NOR-DMARD STUDY

Background: Juvenile idiopathic arthritis (JIA) can cause considerable pain and disability in childhood adulthood. Studies exploring the efficacy of medications adult JIA patients are limited, although tumor necrosis factor inhibitors (TNFi) have been increasingly used this patient group. Objectives: To explore TNFi ± comedication on disease activity patients, compared to a weighted rheumatoid (RA) cohort. Methods: Data from NOR-DMARD, longitudinal observational study including > 18 years starting or switching DMARD treatment, was [1]. Patients with clinical diagnosis, other inflammatory joint diseases diagnosed before 16 were identified population. RA included for comparative purposes. Disease measurements remission rates among treatment collected at baseline, 3 6 months. Changes absolute after months calculated. Remission change baseline between cohort weights based age gender, using linear logistic regression continuous categorical variables, respectively. Results: 281 (68.9% female, mean (SD) 32.1 (11.1) years, diagnosis duration 23.5 (12.2) years) 1374 (71.6% 52.7 (14.5) 9.5 (10.0) analyses. Age, gender distribution differed significantly cohorts. Both groups had significant improvement across all measures (Table 1), which maintained except MHAQ. The group greater 3- 6-month SJC28. an overall increase rates. higher 3-month DAS28 rate (Figure 1). This difference not months, as declined measures. Table 1. Baseline Change JIA* RA* Diff. § ESR, mm/h 18.7 (18.9) 25.5 (22.0) 1.3 (-2.3 4.9) -7.4 (15.8) -7.6 (16.6) -0.3 (-4.4 3.8) (16.8) -8.5 (18.2) 0.0 (-5.7 5.7) SJC28 2.5 (3.6) 5.5 (5.4) 1.6 (1.3 2.0) -1.4 (3.4) -3.1 (4.7) -1.0 (-1.7 -0.3) -1.6 (3.2) -3.5 (5.1) (-1.9 -0.1) TJC 28 4.0 (5.6) 6.6 (6.4) (0.4 2.3) -1.8 (3.9) (5.9) -0.6 (-1.4 0.2) -3.9 (6.2) (-2.0 0.1) 3.6 (1.4) 4.5 (1.6) 0.3 (0.1 0.6) -1.2 (1.3) -0.0 (-0.3 0.3) -1.5 -0.2 (-0.6 SDAI 16.8 (10.6) 23.1 (14.3) 2.4 (0.3 4.5) -7.7 (9.9) -10.9 (12.7) -2.0 (-4.2 -7.9 (8.6) -13.2 (13.6) -2.8 (-5.8 PGA 51.4 (26.3) 49.9 (25.5) -4.0 (-8.5 0.5) -20.6 (26.7) -17.0 2.7 (-2.2 7.6) -21.6 (25.3) -19.1 (28.7) 3.4 (-3.0 9.8) MHAQ 0.6 (0.5) 0.7 (-0.1 -0.24 (0.42) -0.22 0.0(-0.1 -0.23 (0.40) -0.25 (0.45) *Mean Weighted difference, coefficient (95 % confidence interval) Figure Mean error bars (SE) Conclusion: equally effective reducing inducing Absolute measures, studies longer needed long-term groups. References: [1]Kvien, T.K., et al., A Norwegian register: prescriptions DMARDs biological agents rheumatic diseases. Clin Exp Rheumatol, 2005. 23 (5 Suppl 39): p. S188-94. Disclosure Interests: Imane Bardan: None declared, Karen Minde Fagerli: Joe Sexton: Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Liz Marina Paucar Loli: Tore K. Kvien Fees speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, consulting: AbbVie, Biogen, Eli Lilly, Gliead, Mylan, Grant/research support from: Received research funding Diakonhjemmet Hospital BMS, MSD, Pfizer Eirik kristianslund: Anna-Birgitte Aga Dr. reports personal fees Novartis outside submitted work